CD276 and esophageal cancer: Currently, the potential targets against esophageal cancer include MUC1, HER2, EpCAM, EpA2 and CD276, for CAR-T cell therapy, NY-ESO-1, MAGE-A3 and MAGE-A4 for TCR-T cell therapy.